Skip to main content
SpringerLink
Log in

Recombinant human prothrombin kringles have potent anti-angiogenic activities and inhibit Lewis lung carcinoma tumor growth and metastases

  • Published:
Angiogenesis Aims and scope Submit manuscript

Abstract

Prothrombin, a protein involved in blood coagulation, is a plasma glycoprotein composed of the Gla domain, two adjacent kringle domains, and a serine protease domain. Kringles are triple-disulfide-loop folding domains, which are found in several other blood proteins. In this study, we showed that recombinant human prothrombin kringle-1, -2, and -1-2 (rk-1, -2, -1-2) all have potent anti-angiogenic activities, which inhibit Lewis lung carcinoma (LLC) tumor growth and metastases. Recombinant human prothrombin kringles were expressed by an E. coli expression system and purified to apparent homogeneity from crude E. coli extracts. Purified rk-1, -2, -1-2 migrated with a molecular mass of 14, 19, and 31 kDa, respectively, on sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. rk-1, -2, -1-2 exhibited potent inhibitory effects on bFGF-stimulated bovine capillary endothelial cell growth with half-maximal concentrations (ED50) of approximately 41, 55, and 156 nM, respectively. All of the recombinant human prothrombin kringles also inhibited angiogenesis in the chorioallantoic membrane (CAM) of chick embryos at a dose of 20 μg. Systemic administration of rk-1, -2, -1-2 at a dose of 0.5 mg/kg/day suppressed the growth of primary LLC and at dose of 0.5 and 1.0 mg/kg/day inhibited LLC metastases in C57BL6/J mice lungs through their anti-angiogenic effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931–4.

    Google Scholar 

  2. Folkman J, D'Amore P. Blood vessel formation: What is its molecularbasis? Cell 1996; 87: 1153–5.

    Google Scholar 

  3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–64.

    Google Scholar 

  4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and otherdisease. Nat Med 1995; 1: 27–31.

    Google Scholar 

  5. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitorthat mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315–28.

    Google Scholar 

  6. Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157–64.

    Google Scholar 

  7. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689–92.

    Google Scholar 

  8. Cao R, Wu HL, Vwitonmaki N et al. Suppression of angiogenesis and tumor growth by the inhibitor K 1–5 generated by plasminmediated proteolysis. Proc Natl Acad Sci USA 1999; 96: 5728–33.

    Google Scholar 

  9. Kandel J, Bossy-Wetzel E, Radvanyi F et al. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991; 66: 1095–104.

    Google Scholar 

  10. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4–25.

    Google Scholar 

  11. Nguyen M, Watanabe H, Budson AE et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356–61.

    Google Scholar 

  12. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 824–31.

    Google Scholar 

  13. Cao Y, Ji RW, Davidson D et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996; 271: 29461–7.

    Google Scholar 

  14. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149–53.

    Google Scholar 

  15. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitorof angiogenesis and tumorgr owth. Cell 1997; 88: 277–85.

    Google Scholar 

  16. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–7.

    Google Scholar 

  17. Ji WR, Castellino FJ, Chang Y et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 1998; 12: 1731–8.

    Google Scholar 

  18. Cao Y, Chen A, An SSA et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 1997; 272: 22924–8.

    Google Scholar 

  19. Clapp C, Martial JA, Guzman RC et al. The 16-kilodalton Nterminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993; 133: 1292–9.

    Google Scholar 

  20. Gupta SK, Hassel T, Singh JP. A potent inhibitorof endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 1995; 92: 7799–803.

    Google Scholar 

  21. Brooks PC, Silletti S, Schalscha TL et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391–400.

    Google Scholar 

  22. Cao Y. Endogenous angiogenesis inhibitors and their theraupetic implications. Int J Biochem Cell Biol 2001; 33: 357–69.

    Google Scholar 

  23. Rhim T, Park C-S, Kim E, Kim SS. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem Biophys Res Commun 1998; 252: 513–6.

    Google Scholar 

  24. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 1988; 57: 915–56.

    Google Scholar 

  25. Mann KG, Nesheim ME, Church WR et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1–16.

    Google Scholar 

  26. Lee TH, Rhim T, Kim SS. Prothrombin kringle 2 domain has growth inhibitory activity against bFGF-stimulated capillary endothelial cell. J Biol Chem 1998; 273: 28805–12.

    Google Scholar 

  27. Rhim T, Kim E, Park C-S, Kim SS. Expression, purification, and characterization of prothrombin kringle 2. J Biochem Mol Biol 1999; 31: 156–60.

    Google Scholar 

  28. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350–4.

    Google Scholar 

  29. Sim BKL, O'reilly MS, Liang H et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997; 57: 1329–34.

    Google Scholar 

  30. Cao Y, O'Reilly MS, Marshall B et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998; 101: 1055–63.

    Google Scholar 

  31. Folkman J. Tumorangiogenesis: Therapeutic implications. New Engl J Med 1971; 285: 1182–6.

    Google Scholar 

  32. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (London) 1993; 362: 841–4.

    Google Scholar 

  33. Lin P, Polverini P, Dewhirst M et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie 2 in pathologic vascular growth. J Clin Invest 1997; 100: 2072–8.

    Google Scholar 

  34. Millauer B, Shawver LK, Plate KH et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (London) 1994; 367: 576–9.

    Google Scholar 

  35. Brooks PC, Stromblad S, Klemke R et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815–22.

    Google Scholar 

  36. Ingber D, Fujita T, Kishimoto S et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (London) 1990; 348: 555–7.

    Google Scholar 

  37. Browder T, Folkman J, Shepherd SP. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521–4.

    Google Scholar 

  38. Folkman J, Browder T, Palmblad J. Angiogenesis research: Guidelines for translation to clinical application. Thromb Haemost 2001; 86: 23–33.

    Google Scholar 

  39. Good DJ, Polverini PJ, Rastinejad F et al. A tumor suppressor dependent inhibitorof angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624–8.

    Google Scholar 

  40. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochem Biophys Acta 2000; 1477: 267–83.

    Google Scholar 

  41. Hiraoka N, Allen E, Apel IJ et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95: 365–77.

    Google Scholar 

  42. Zhou Z, Apte SS, Soininen R et al. Impaired endochondral ossification and angiogenesis, and early lethality in mice deficient in membrane type matrix metalloproteinase I (MT1-MMP). Proc Natl Acad Sci USA 2000; 97: 4052–7.

    Google Scholar 

  43. Yamaguchi N, Anand-Apte B, Lee M et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999; 18: 4414–23.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, College of Science, Yonsei University, Seoul, Korea

    Tae H. Kim, Eunkyung Kim, Dongwon Yoon, Jaebeum Kim, Tai Y. Rhim & Soung S. Kim

Authors
  1. Tae H. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eunkyung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dongwon Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jaebeum Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tai Y. Rhim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Soung S. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Soung S. Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, T.H., Kim, E., Yoon, D. et al. Recombinant human prothrombin kringles have potent anti-angiogenic activities and inhibit Lewis lung carcinoma tumor growth and metastases. Angiogenesis 5, 191–201 (2002). https://doi.org/10.1023/A:1023835102832

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1023835102832

Search

Navigation